Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
18
CVM Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
15.75%
Day range:
$0.27 - $0.33
52-week range:
$0.27 - $2.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.94x
Volume:
18.5M
Avg. volume:
1.6M
1-year change:
-85.87%
Market cap:
$21.9M
Revenue:
--
EPS (TTM):
-$0.48
Analysts' Opinion
-
Consensus RatingCEL-SCI has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.40, CEL-SCI has an estimated upside of 2504.72% from its current price of $0.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $0.28.
Fair Value
-
According to the consensus of 1 analyst, CEL-SCI has 2504.72% upside to fair value with a price target of $7.40 per share.
CVM vs. S&P 500
-
Over the past 5 trading days, CEL-SCI has underperformed the S&P 500 by -11.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CEL-SCI does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CEL-SCI has grown year-over-year revenues for 1 quarter straight. In the most recent quarter CEL-SCI reported revenues of --.
Earnings Growth
-
CEL-SCI has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CEL-SCI reported earnings per share of -$0.11.
Enterprise value:
17.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$34.9M | -$30.3M | -$26.8M | -$6.5M | -$6.9M | |
| EBITDA | -$30.9M | -$26.4M | -$22.6M | -$5.5M | -$5.9M | |
| Diluted EPS | -$0.85 | -$0.68 | -$0.48 | -$0.14 | -$0.11 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.7M | $41.9M | $20.4M | $6.2M | $5.9M | |
| Total Assets | $49.6M | $69.7M | $44.6M | $28.7M | $25.7M | |
| Current Liabilities | $7.3M | $3.3M | $4.7M | $4.9M | $5.5M | |
| Total Liabilities | $20.8M | $18.3M | $18M | $16.1M | $14.4M | |
| Total Equity | $28.8M | $51.4M | $26.6M | $12.7M | $11.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.1M | -$23.1M | -$18.1M | -$4.9M | -$4.1M | |
| Cash From Investing | -$674.4K | -$383.5K | -$76.2K | -$64.9K | -$33K | |
| Cash From Financing | -$316.5K | $8.7M | $19.5M | $4M | $4M | |
| Free Cash Flow | -$18.8M | -$23.5M | -$18.1M | -$5M | -$4.2M | |
CVM
Sector
Market Cap
$21.9M
$37.4M
Price % of 52-Week High
11.89%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-85.87%
-38.36%
Beta (5-Year)
0.666
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.32
200-day SMA
Sell
Level
$0.86
Bollinger Bands (100)
Sell
Level
0.36 - 0.74
Chaikin Money Flow
Sell
Level
-464.6M
20-day SMA
Sell
Level
$0.36
Relative Strength Index (RSI14)
Sell
Level
33.95
ADX Line
Sell
Level
12.5
Williams %R
Buy
Level
-85.9
50-day SMA
Sell
Level
$0.38
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
232.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Stock Forecast FAQ
In the current month, CVM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CVM average analyst price target in the past 3 months is $7.40.
-
Where Will CEL-SCI Stock Be In 1 Year?
According to analysts, the consensus estimate is that CEL-SCI share price will rise to $7.40 per share over the next 12 months.
-
What Do Analysts Say About CEL-SCI?
Analysts are divided on their view about CEL-SCI share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CEL-SCI is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is CEL-SCI's Price Target?
The price target for CEL-SCI over the next 1-year time period is forecast to be $7.40 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CEL-SCI is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CVM?
You can purchase shares of CEL-SCI via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CEL-SCI shares.
-
What Is The CEL-SCI Share Price Today?
CEL-SCI was last trading at $0.28 per share. This represents the most recent stock quote for CEL-SCI. Yesterday, CEL-SCI closed at $0.28 per share.
-
How To Buy CEL-SCI Stock Online?
In order to purchase CEL-SCI stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
48
SMTC alert for Mar 18
Semtech [SMTC] is down 0.49% over the past day.
Buy
67
PLPC alert for Mar 18
Preformed Line Products [PLPC] is up 3.8% over the past day.
Buy
58
NUTX alert for Mar 18
Nutex Health [NUTX] is up 4.82% over the past day.
